AUArun Urs

Arun Urs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arun Urs has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • David C. Wilson

    Child Life and Health, Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK

    2 shared publications
  • Zuzana Londt

    Department of Paediatric Gastroenterology, Sheffield Children’s NHS Foundation Trust, Sheffield, UK

    2 shared publications
  • A Bond Md Md(Res)

    Department of Gastroenterology, Royal Liverpool and Broadgreen Hospitals, Liverpool, UK

    1 shared publication
  • A Urs Mbbs Frcpch

    Paediatric Gastroenterology, Sheffield Children's Hospital, Sheffield, UK

    1 shared publication
  • A. Bond

    Department of Gastroenterology Royal Liverpool and Broadgreen Hospitals Liverpool UK

    1 shared publication
  • A. Rodrigues

    Department of Paediatric Gastroenterology Oxford University Hospitals NHS Foundation Trust Oxford UK

    1 shared publication

Latest Publications

  • Initial effectiveness and safety data on intravenous ferric derisomaltose for iron deficiency anaemia management in paediatric gastroenterology patients: a multicentre retrospective cohort study

    by Laura Gianolio, Shaun Emmitt, Maureen Nwabueze, Peter Gillett, Victoria Merrick, Rosalind Rabone, Kat Armstrong, Catherine Paxton, Ewan Swann, Prithvi Rao, et al.

    Objective Iron deficiency anaemia (IDA) is common in paediatric gastroenterology with intravenous iron increasingly utilised. While adult data are published for ferric derisomaltose (FDI), no paediatric data exist. Our aim was to assess the effectiveness and safety profile of FDI in paediatric gastroenterology. Design Retrospective cohort study. Setting Two UK referral centres (Edinburgh and Sheffield). Patients All paediatric gastroenterology patients who received FDI from June 2020 to June 2023. Main outcome measures Haematological and biochemical parameters were collected before and at 1, 3, 6 and 12 months after treatment, when available, together with the need for repeated FDI infusions and FDI adverse events. Results Sixty-five patients were identified (54% male; median age 12.8 years, IQR 9.6–15.2), receiving 78 FDI infusions. After a single infusion, 38/59 (64%) patients (effectiveness analysis) completely corrected their anaemia and 6/59 (10%) improved from moderate-severe to mild anaemia. Median haemoglobin increased from 92 (IQR 85–108) to 126 (IQR 115–132) g/L at 1 month (pConclusions Our real-world data reveal FDI is rapidly and persistently effective in correcting IDA in paediatric gastroenterology. No significant biochemical alterations or new safety signals were identified.


  • Open Access

    1275 D lactic acidosis – is it more prevalent condition than we think?

    by Ruth Kwasba, Micheal Nwosu, Sunita Rajani, Zuzana Londt, Katie Green, Arun Urs

    Background D-lactic acidosis is a known complication in children with short bowel syndrome. The unabsorbed carbohydrates are fermented by colonic bacteria to form D-lactic acid among other organic acids. They typically present with episodic metabolic acidosis and characteristic neurologic abnormalities including confusion, ataxia and slurred speech. Routine clinical assessment of serum lactate covers only L-lactic acid; when clinical suspicion for D-lactic acidosis is high, special assays for D-lactic acid are needed. Standard treatment consists of restricting oral carbohydrates or fasting, correction of acidosis, and long-term suppression of pathogenic floras with antibiotics. Objectives To create more awareness of D-lactic acidosis and promote early detection as well as more effective management. Methods A retrospective case notes review with short bowel syndrome identified 3 children presenting with d-lactic acidosis over a 10-year period at tertiary care hospital. ResultsAll 3 patients presented with neurological symptoms which pose a diagnostic challenge as often confused with primary neurological disorder. All the differential diagnosis including nutritional, metabolic and neurological was considered and excluded. The acute episode management included IV fluids, sodium bicarbonate correction, strict restriction of enteral carbohydrates with resolution of symptoms within 24–48 hours. Patient 2 required insulin which helped resolve the acidosis swiftly. She continued to present with recurrent D lactic acidosis despite low carbohydrate diet, cycling antibiotics, STEPP procedure for bowel dilatation, D lactate free probiotics and currently established on partial parenteral nutrition. Patient 1 is doing well on carbohydrate restricted diet only. Patient 3 remains on restricted diet, antibiotics with active weaning of parenteral nutrition. Recolonization of the intestine with non-pathogenic floras remains a long-term treatment goal. Conclusions D lactic acidosis is an uncommon condition, but likely an under recognized syndrome. Physicians should be aware of the risk factors and presenting symptoms while keeping a high index of suspicion, as early detection leads to effective management of the condition. Diagnosis is made by a combination of clinical and laboratory data including special assays for D-lactate. Although there is safe and effective treatment strategies, multidisciplinary approach, compliance to dietary recommendations help reduce the incidence but in rare cases novel emerging therapies need to be considered.

  • Open Access

    COVID‐19 infection in patients with intestinal failure: UK experience

    by P. J. Allan, T. Ambrose, C. Mountford, A. Bond, C. Donnellan, R. Boyle, C. Calvert, E. Cernat, E. Clarke, S. C. Cooper, et al.

    Background: The direct effect of the coronavirus disease 2019 (COVID‐19) pandemic on patients with intestinal failure (IF) has not been described.Methods: We conducted a nationwide study of UK IF centers to evaluate the infection rates, presentations, and outcomes in patients with types 2 and 3 IF.Results: A total of 45 patients with IF contracted COVID‐19 between March and August 2020; this included 26 of 2191 (1.2%) home parenteral nutrition (HPN)–dependent adults and 19 of 298 (6.4%) adults hospitalized with type 2 IF. The proportion of patients receiving nursing care for HPN administration was higher in those with community‐acquired COVID‐19 (66.7%) than the proportion in the entire HPN cohort (26.1%; P < .01). Two HPN‐dependent and 1 hospitalized patient with type 2 IF died as a direct consequence of the virus (6.7% of 45 patients with types 2 or 3 infected).Conclusion: This is the first study to describe the outcomes of COVID‐19 in a large cohort of patients requiring long‐term PN. Methods to reduce hospital and community nosocomial spread would likely be beneficial.


  • Open Access

    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel

    by Richard Hansen, Susanna Meade, R Mark Beattie, Marcus Kh Auth, Nick Croft, Philip Davies, David Devadason, Conor Docherty, Jenny Epstein, Lucy Howarth, et al.

    Objective Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-2/COVID-19 pandemic is challenging due to reliance on immunosuppression and the potential for surgery. We aimed to provide COVID-19-specific guidance using the European Crohn’s and Colitis Organisation/European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for comparison. Design We convened a RAND appropriateness panel comprising 14 paediatric gastroenterologists and paediatric experts in surgery, rheumatology, respiratory and infectious diseases. Panellists rated the appropriateness of interventions for ASC in the context of the COVID-19 pandemic. Results were discussed at a moderated meeting prior to a second survey. Results Panellists recommended patients with ASC have a SARS-CoV-2 swab and expedited biological screening on admission and should be isolated. A positive swab should trigger discussion with a COVID-19 specialist. Sigmoidoscopy was recommended prior to escalation to second-line therapy or colectomy. Methylprednisolone was considered appropriate first-line management in all, including those with symptomatic COVID-19. Thromboprophylaxis was also recommended in all. In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. Delaying colectomy due to SARS-CoV-2 infection was considered inappropriate. Corticosteroid tapering over 8–10 weeks was deemed appropriate for all. After successful corticosteroid rescue, thiopurine maintenance was rated appropriate in patients with negative SARS-CoV-2 swab and asymptomatic patients with positive swab but uncertain in symptomatic COVID-19. Conclusion Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status. Consideration of routine prophylactic anticoagulation was recommended.